Drug intelligence / Profile preview

odm-103

Development stage: Phase 1
Lead developer: Orion
Modality: Small Molecules
Administration: Oral

Overview

ODM-103 is a small molecule drug developed as a catechol-O-methyl transferase (COMT) inhibitor. It was designed to enhance the effects of levodopa in the treatment of Parkinson’s disease by inhibiting COMT, an enzyme that degrades catecholamines such as dopamine. Preclinical studies indicated that ODM-103 is more effective than entacapone, another COMT inhibitor. The drug entered Phase 1 clinical trials to assess safety and tolerability in healthy volunteers but development was discontinued after this stage[1][5][9].

Other names: ODM-103ODM103ODM 103

Targets

COMT (Catechol-O-methyltransferase)

Beyond the preview

Go deeper on odm-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on odm-103.

Explore the full profile